Bharat Biotech to roll-out intranasal COVID-19 vaccine at Rs 800 for private market
27 December 2022 | News
iNCOVACC to be priced at Rs 325 / dose for large volume procurement by State Governments and Govt of India
Hyderabad-based Bharat Biotech has announced that iNCOVACC (BBV154), is scheduled to be introduced in the country as a booster dose shortly. Earlier this month, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC.
The vaccine is now available on CoWin, and priced at Rs 800 for private markets and priced at Rs 325 for supplies to Govt of India and State Governments.
iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.
As a needle-less vaccination, Bharat Biotech's iNCOVACC will be India's first such booster dose. India will now have more options when it comes to third doses or precautionary doses.
Despite the lack of demand for COVID-19 vaccines, Bharat Biotech continued product development in intranasal vaccines, to be well-prepared with platform technologies for future infectious diseases.
iNCOVACC is stable at 2-8°C for easy storage and distribution. Bharat Biotech has established large manufacturing capabilities at multiple sites across India, including Gujarat, Karnataka, Maharashtra and Telangana, with operations pan India.
